The intron-22-inverted F8 locus permits factor VIII synthesis: Explanation for low inhibitor risk and a role for pharmacogenomics

Blood

Volumn 125, Issue 2, 2015, Pages 223-228

  Sauna, Zuben E ^a   Lozier, Jay N ^b   Kasper, Carol K ^c,d   Yanover, Chen ^e   Nichols, Timothy ^f   Howard, Tom E ^d,g,h  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Orthopaedic Hemophilia Treatment Center   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e IBM HAIFA RESEARCH LAB   (Israel)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; HLA ANTIGEN CLASS 2; RECOMBINANT FACTOR VIII SQ;

AMINO ACID SEQUENCE; ARTICLE; GENE LOCUS; GENE MUTATION; HUMAN; INTRON; ISOMER; MAJOR HISTOCOMPATIBILITY COMPLEX; PHARMACOGENOMICS; PRIORITY JOURNAL; CHROMOSOME INVERSION; GENETICS; HEMOPHILIA A; IMMUNOLOGY; MUTATION; PHARMACOGENETICS;

CHROMOSOME INVERSION; FACTOR VIII; HEMOPHILIA A; HUMANS; INTRONS; MUTATION; PHARMACOGENETICS;

EID: 84920964361     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-530113     Document Type: Article

References (31)

1. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12):2922-2934.
2. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to FVIII and FIX. Haemophilia. 2006;12(Suppl 6):15-22.
3. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia. 2002;8(Suppl 2):23-29.
4. Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86(6):2206-2212.
5. Pandey GS, Yanover C, Miller-Jenkins LM, et al PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nat Med. 2013;19(10):1318-1324.
6. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol. 2003;21:139-176.
7. Peerlinck K, Jacquemin MG, Arnout J, et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood. 1999;93(7):2267-2273.
8. Fijnvandraat K, Turenhout EA, van den Brink EN, et al. The missense mutation Arg593 -. Cys is related to antibody formation in a patient with mild hemophilia A. Blood. 1997;89(12): 4371-4377.
9. Thompson AR, Murphy ME, Liu M, et al. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood. 1997;90(5):1902-1910.
10. Bogdanova N, Markoff A, Eisert R, et al. Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A. Hum Mutat. 2007;28(1):54-60.
11. Eckhardt CL, van Velzen AS, Peters M, et al; INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122(11):1954-1962.
12. Viel KR, Machiah DK, Warren DM, et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood. 2007;109(9):3713-3724.
13. Pandey GS, Yanover C, Howard TE, Sauna ZE. Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment. PLOS Comput Biol. 2013;9(5): e1003066.
14. Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009;360(16):1618-1627.
15. Miller CH, Benson J, Ellingsen D, et al; Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012;18(3):375-382.
16. Schwarz J, Astermark J, Menius ED, et al; Hemophilia Inhibitor Genetics Study Combined Cohort. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia. 2013;19(1):113-118.
17. Tiede A, Eisert R, Czwalinna A, Miesbach W, Scharrer I, Ganser A. Acquired haemophilia caused by non-haemophilic factor VIII gene variants. Ann Hematol. 2010;89(6):607-612.
18. Rost S, Löffler S, Pavlova A, Müller CR, Oldenburg J. Detection of large duplications within the factor VIII gene by MLPA. J Thromb Haemost. 2008;6(11):1996-1999.
19. White GC II, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost. 2005;3(8):1676-1681.
20. Isken O, Maquat LE. Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function. Genes Dev. 2007;21(15):1833-1856.
21. Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet. 1993;5(3):236-241.
22. Levinson B, Kenwrick S, Gamel P, Fisher K, Gitschier J. Evidence for a third transcript from the human factor VIII gene. Genomics. 1992;14(3):585-589.
23. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol. 2006;24:571-606.
24. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol. 2009;9(12):833-844.
25. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557-569.
26. Poon IKH, Lucas CD, Rossi AG, Ravichandran KS. Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol. 2014;14(3):166-180.
27. Yanover C, Jain N, Pierce G, Howard TE, Sauna ZE. Pharmacogenetics and the immunogenicity of protein therapeutics. Nat Biotechnol. 2011;29(10):870-873.
28. Karosiene E, Rasmussen M, Blicher T, Lund O, Buus S, Nielsen M. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ. Immunogenetics. 2013;65(10):711-724.
29. Lazarski CA, Chaves FA, Jenks SA, et al. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity. 2005;23(1):29-40.
30. Sauna ZE, Pandey GS, Jain N, Mahmood I, Kimchi-Sarfaty C, Golding B. Plasma derivatives: new products and new approaches. Biologicals. 2012;40(3):191-195.
31. Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N, Khan MA, Yanover C, Sauna ZE. Building better drugs: developing and regulating engineered therapeutic proteins. Trends Pharmacol Sci. 2013;34(10):534-548.